Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because …  sure enough … here we are again, staring down the laptop and sorting out the growing to-do list. But what can you do? The world keeps spinning — unless you subscribe to flat-earth conspiracies, among others. Well, that is a discussion best left for another day. Meanwhile, there is work to do. So here are a few items of interest to get you going. Hope you conquer the world and do keep in touch if something saucy emerges. …

Pfizer (PFE) and BioNTech (BNTX) said the Food and Drug Administration has granted priority review designation to their application for full approval of their Covid-19 vaccine, and an FDA official said a decision is likely to come within two months, CNN tells us. The companies are seeking approval for the two-dose series for people age 16 and older, and expects to apply for approval for people ages 12 to 15 when the data are available. The agency considers this matter a priority.

The FDA will temporarily allow certain manufacturers to distribute generic versions of the anti-smoking drug varenicline with elevated levels of an impurity that may cause cancer. The agency is doing so in order to maintain availability after Pfizer halted global distribution of its Chantix brand-name drug last month. Agency scientists evaluated the risk of exposure at interim acceptable intake levels up to 185 mg per day and determined that it presents minimal additional cancer risk, according to an FDA statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment